Overview

Next Generation Cancer Diagnostics Market is poised to register a CAGR of 10.5% during the forecast period 2022 to 2028.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Next Generation Cancer Diagnostics Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Next Generation Cancer Diagnostics Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Next Generation Cancer Diagnostics Market:
• Janssen Global Services, LLC
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V.
• Abbott
• GE Healthcare.
• Thermo Fisher Scientific, Inc.
• Agilent Technologies (Dako)
• Illumina, Inc.
• Qiagen
• Cepheid
• Opko Health, Inc.
• Hologic, Inc (Gen-Probe)
• Perkin Elmer, Inc.
• Sysmex Corporation
• Myriad Genetics, Inc.
• Almac Group
• Exosome Diagnostics, Inc.
• Genomic Health, Inc.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Next Generation Cancer Diagnostics Market Segmentation:
By Technology
• Next Generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays

By Application
• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

By Cancer Type
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others

By Function
• Therapeutic Monitoring
• Companion Diagnostics
• Prognostics
• Cancer Screening
• Risk Analysis

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Next Generation Cancer Diagnostics Market By Technology, By Application, By Cancer Type, By Function and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- Technology launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Next Generation Cancer Diagnostics Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Next Generation Cancer Diagnostics Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Next Generation Cancer Diagnostics Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Next Generation Cancer Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Next Generation Sequencing
   7.2. qPCR & Multiplexing
   7.3. Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
   7.4. Protein Microarrays
   7.5. DNA Microarrays

8. Next Generation Cancer Diagnostics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Biomarker Development
   8.2. CTC Analysis
   8.3. Diagnosis
   8.4. Epigenetic Analysis
   8.5. Genetic Analysis

9. Next Generation Cancer Diagnostics Market, By Cancer Type Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Lung Cancer
   9.2. Breast Cancer
   9.3. Colorectal Cancer
   9.4. Cervical Cancer
   9.5. Others

10. Next Generation Cancer Diagnostics Market, By Function Historical Analysis and Forecast 2022-2028 (USD Million)  
    10.1. Therapeutic Monitoring
    10.2. Companion Diagnostics
    10.3. Prognostics
    10.4. Cancer Screening
    10.5. Risk Analysis

11. North America Next Generation Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. U.S.A
          11.2.2. Canada
          11.2.3. Mexico
    11.3. Market Size (USD Million) Forecast for North America 2022-2028

12. Latin America Next Generation Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Brazil
          12.2.2. Venezuela
          12.2.3. Argentina
          12.2.4. Rest of Latin America
    12.3. Market Size (USD Million) Forecast for Latin America 2022-2028

13. Europe Next Generation Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Germany
          13.2.2. U.K         
          13.2.3. France
          13.2.4. Italy
          13.2.5. Spain
          13.2.6. Russia
          13.2.7. Poland
          13.2.8. Rest of Europe
    13.3. Market Size (USD Million) Forecast for Europe 2022-2028

14. Asia Pacific Next Generation Cancer Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Japan
          14.2.2. China
          14.2.3. India
          14.2.4. Australia and New Zealand
          14.2.5. ASEAN
          14.2.6. Rest of Asia Pacific
    14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    15.1. Introduction
    15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          15.2.1. GCC
          15.2.2. Israel
          15.2.3. South Africa
          15.2.4. Rest of MEA
    15.3. Market Size (USD Million) Forecast for MEA 2022-2028

16. Market Share Analysis and Competitive Landscape   
    16.1. Global Landscape - Key Players, Revenue and Presence
    16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    16.3. Global Emerging Companies
    16.4. North America - Market Share Analysis and Key Regional Players
    16.5. Europe - Market Share Analysis and Key Regional Players
    16.6. Asia Pacific - Market Share Analysis and Key Regional Players
    16.7. Global Key Player - Growth Matrix

17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
   17.1. Janssen Global Services, LLC
         17.1.1. Company Overview
         17.1.2. Technology Portfolio
         17.1.3. SWOT Analysis
         17.1.4. Financial Overview
         17.1.5. Strategic Overview
   17.2. Novartis AG
         17.2.1. Company Overview
         17.2.2. Technology Portfolio
         17.2.3. SWOT Analysis
         17.2.4. Financial Overview
         17.2.5. Strategic Overview
   17.3. F. Hoffmann-La Roche Ltd
         17.3.1. Company Overview
         17.3.2. Technology Portfolio
         17.3.3. SWOT Analysis
         17.3.4. Financial Overview
         17.3.5. Strategic Overview
   17.4. Koninklijke Philips N.V.
         17.4.1. Company Overview
         17.4.2. Technology Portfolio
         17.4.3. SWOT Analysis
         17.4.4. Financial Overview
         17.4.5. Strategic Overview
   17.5. Abbott
         17.5.1. Company Overview
         17.5.2. Technology Portfolio
         17.5.3. SWOT Analysis
         17.5.4. Financial Overview
         17.5.5. Strategic Overview          
   17.6. GE Healthcare
         17.6.1. Company Overview
         17.6.2. Technology Portfolio
         17.6.3. SWOT Analysis
         17.6.4. Financial Overview
         17.6.5. Strategic Overview      
   17.7. Thermo Fisher Scientific, Inc.
         17.7.1. Company Overview
         17.7.2. Technology Portfolio
         17.7.3. SWOT Analysis
         17.7.4. Financial Overview
         17.7.5. Strategic Overview
   17.8. Agilent Technologies (Dako)
         17.8.1. Company Overview
         17.8.2. Technology Portfolio
         17.8.3. SWOT Analysis
         17.8.4. Financial Overview
         17.8.5. Strategic Overview
   17.9. Illumina, Inc.
         17.9.1. Company Overview
         17.9.2. Technology Portfolio
         17.9.3. SWOT Analysis
         17.9.4. Financial Overview
         17.9.5. Strategic Overview
   17.10.Qiagen.
         17.10.1. Company Overview
         17.10.2. Technology Portfolio
         17.10.3. SWOT Analysis
         17.10.4. Financial Overview
         17.10.5. Strategic Overview
   17.11.Cepheid
         17.11.1. Company Overview
         17.11.2. Technology Portfolio
         17.11.3. SWOT Analysis
         17.11.4. Financial Overview
         17.11.5. Strategic Overview
   17.12.Opko Health, Inc.
         17.12.1. Company Overview
         17.12.2. Technology Portfolio
         17.12.3. SWOT Analysis
         17.12.4. Financial Overview
         17.12.5. Strategic Overview
   17.13.Hologic, Inc (Gen-Probe)
         17.13.1. Company Overview
         17.13.2. Technology Portfolio
         17.13.3. SWOT Analysis
         17.13.4. Financial Overview
         17.13.5. Strategic Overview
   17.14.Perkin Elmer, Inc.
         17.14.1. Company Overview
         17.14.2. Technology Portfolio
         17.14.3. SWOT Analysis
         17.14.4. Financial Overview
         17.14.5. Strategic Overview  
   17.15.Sysmex Corporation
         17.15.1. Company Overview
         17.15.2. Technology Portfolio
         17.15.3. SWOT Analysis
         17.15.4. Financial Overview
         17.15.5. Strategic Overview  
   17.16.Myriad Genetics, Inc.
         17.16.1. Company Overview
         17.16.2. Technology Portfolio
         17.16.3. SWOT Analysis
         17.16.4. Financial Overview
         17.16.5. Strategic Overview  
   17.17.Almac Group
         17.17.1. Company Overview
         17.17.2. Technology Portfolio
         17.17.3. SWOT Analysis
         17.17.4. Financial Overview
         17.17.5. Strategic Overview  
   17.18.Exosome Diagnostics, Inc.
         17.18.1. Company Overview
         17.18.2. Technology Portfolio
         17.18.3. SWOT Analysis
         17.18.4. Financial Overview
         17.18.5. Strategic Overview  
   17.19.Genomic Health, Inc.
         17.19.1. Company Overview
         17.19.2. Technology Portfolio
         17.19.3. SWOT Analysis
         17.19.4. Financial Overview
         17.19.5. Strategic Overview

18. Pre and Post COVID-19 Impact
    18.1. Positive influence on the healthcare industry
    18.2. The financial disruption of the manufacturing sector
    18.3. Impact of COVID-19 on emerging companies
    18.4. Significant mandates in the healthcare regulations initiated by administrations
    18.5. The overall economic slowdown of the developing and developed nations

19. FutureWise SME Key Takeaway Points for Client

Tables

Figures